Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-09-24
2009-10-20
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S337000, C514S470000, C544S124000, C546S193000, C546S279100, C546S284100, C549S467000
Reexamination Certificate
active
07605158
ABSTRACT:
The present invention provides a carbamoyl-type benzofuran derivative of the formula [1]:wherein Ring Z is a group of the formula:etc.; A is a single bond, and the like; Y is a cycloalkanediyl group, etc.; R4and R5are the same or different and each is an optionally substituted lower alkyl group, etc.; R1is a halogen atom, etc.; Ring B of the formula:is an optionally substituted benzene ring; and R3is a hydrogen atom. etc., or a pharmaceutically acceptable salt thereof, which is useful as an FXa inhibitor.
REFERENCES:
patent: 5635527 (1997-06-01), Ono et al.
patent: 5753670 (1998-05-01), Ono et al.
patent: 6140351 (2000-10-01), Amaiz et al.
patent: 6380221 (2002-04-01), Amaiz et al.
patent: 6498185 (2002-12-01), Amaiz et al.
patent: 6635657 (2003-10-01), Beight et al.
patent: 6686368 (2004-02-01), Zhu et al.
patent: 6759414 (2004-07-01), Beight et al.
patent: 2004/0029874 (2004-02-01), Beight et al.
patent: WO-95/33720 (1995-12-01), None
patent: WO-99/32477 (1999-07-01), None
patent: WO-99/32477 (1999-07-01), None
patent: WO-99/42439 (1999-08-01), None
patent: WO-00/39118 (2000-07-01), None
patent: WO-00/39118 (2000-07-01), None
patent: WO-01/19788 (2001-03-01), None
patent: WO-02/12189 (2002-02-01), None
patent: WO-02/079145 (2002-10-01), None
patent: WO-03/082847 (2003-10-01), None
patent: WO-2004/063202 (2004-07-01), None
Roy, K et al., Drug Design and Discovery, 2002, 18, pp. 23 to 31.
Roy, K. et al., Drug and Design and Discovery, 2002, 18, pp. 33 to 43.
Roy, K. et al., Drug Design and Discovery, 2002, 18, pp. 23 to 31.
Freedman, “Oral Anticoagulants: Pharmacodynamics, Clinical Indications and Adverse Effects”, Journal of Clinical Pharmacology, vol. 32, pp. 196-209, 1992.
Hirsh, “Oral Antiocoagulant Drugs”, The New England Journal of Medicine, vol. 324, No. 26, pp. 1865-1875, 1991.
Sixma, et al., “The Ideal Anti-Thrombotic Drug”, Thrombosis Research, Erratum, vol. 68, No. 6, pp. 507-512, 1992.
Matsuo, “t-PA and Pro-UK”, Gakusaikikaku, pp. 5-40, 1986.
Kaiser, et al., “Pharmacological Characterization of a New Highly Effective Synthetic Thrombin Inhibitor”, Biomed Biochim Acta, vol. 44, 7/8, pp. 1201-1210, 1985.
Tidwell, et al., “Strategies for Anticoagulation with Synthetic Protease Inhibitors, Xa Inhibitors Versus Thrombin Inhibitors”, Thrombosis Research, vol. 19, pp. 339-349, 1980.
Harwalkar, et al., “Synthesis and Reactions of 2-Substituted-4H-Benzofuro[3,2-d]-m-Oxazin-4-Ones”, Indian Journal of Heterocyclic Chemistry, vol. 3, pp. 247-252, 1994.
Viti, et al., “Synthesis of New Arylbenzofurodiazepin-6-Ones”, Journal of Heterocyclic Chemistry, 27(5), pp. 1369-1375, 1990.
Akatsuka Hidenori
Iijima Toru
Kawaguchi Takayuki
Morimoto Masamichi
Murakami Jun
Birch & Stewart Kolasch & Birch, LLP
Dentz Bernard
Mitsubishi Tanabe Pharma Corporation
LandOfFree
Carbamoyl-type benzofuran derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbamoyl-type benzofuran derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbamoyl-type benzofuran derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4116103